Basilea Pharmaceutica Future Growth
Future criteria checks 5/6
Basilea Pharmaceutica is forecast to grow earnings and revenue by 20.1% and 6% per annum respectively. EPS is expected to grow by 20.2% per annum. Return on equity is forecast to be 83.8% in 3 years.
Key information
20.1%
Earnings growth rate
20.2%
EPS growth rate
| Biotechs earnings growth | 37.0% |
| Revenue growth rate | 6.0% |
| Future return on equity | 83.8% |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 249 | 74 | 59 | 58 | 3 |
| 12/31/2025 | 222 | 46 | 54 | 49 | 5 |
| 12/31/2024 | 205 | 61 | 59 | 57 | 4 |
| 6/30/2024 | 149 | -1 | 9 | 10 | N/A |
| 3/31/2024 | 153 | 5 | 11 | 12 | N/A |
| 12/31/2023 | 158 | 10 | 13 | 14 | N/A |
| 9/30/2023 | 166 | 33 | 20 | 22 | N/A |
| 6/30/2023 | 175 | 56 | 27 | 29 | N/A |
| 3/31/2023 | 161 | 34 | 16 | 18 | N/A |
| 12/31/2022 | 148 | 12 | 4 | 7 | N/A |
| 9/30/2022 | 150 | 6 | -2 | 1 | N/A |
| 6/30/2022 | 152 | 1 | -8 | -5 | N/A |
| 3/31/2022 | 150 | -3 | -20 | -18 | N/A |
| 12/31/2021 | 148 | -7 | -33 | -32 | N/A |
| 9/30/2021 | 130 | -26 | -41 | -40 | N/A |
| 6/30/2021 | 112 | -45 | -50 | -48 | N/A |
| 3/31/2021 | 120 | -30 | -53 | -51 | N/A |
| 12/31/2020 | 128 | -15 | -56 | -54 | N/A |
| 9/30/2020 | 134 | -6 | -55 | -53 | N/A |
| 6/30/2020 | 141 | 3 | -53 | -52 | N/A |
| 3/31/2020 | 137 | -10 | -58 | -58 | N/A |
| 12/31/2019 | 134 | -22 | -64 | -64 | N/A |
| 9/30/2019 | 135 | -23 | -64 | -64 | N/A |
| 6/30/2019 | 136 | -24 | -65 | -64 | N/A |
| 3/31/2019 | 134 | -28 | -72 | -72 | N/A |
| 12/31/2018 | 133 | -31 | -80 | -79 | N/A |
| 9/30/2018 | 124 | -26 | -43 | -42 | N/A |
| 6/30/2018 | 115 | -21 | -6 | -5 | N/A |
| 3/31/2018 | 108 | -20 | N/A | 7 | N/A |
| 12/31/2017 | 102 | -19 | N/A | 19 | N/A |
| 9/30/2017 | 92 | -32 | N/A | -19 | N/A |
| 6/30/2017 | 82 | -44 | N/A | -58 | N/A |
| 3/31/2017 | 74 | -48 | N/A | -66 | N/A |
| 12/31/2016 | 66 | -51 | N/A | -75 | N/A |
| 9/30/2016 | 62 | -55 | N/A | -89 | N/A |
| 6/30/2016 | 58 | -59 | N/A | -102 | N/A |
| 3/31/2016 | 55 | -61 | N/A | -85 | N/A |
| 12/31/2015 | 53 | -62 | N/A | -68 | N/A |
| 9/30/2015 | 50 | -57 | N/A | -57 | N/A |
| 6/30/2015 | 47 | -52 | N/A | -46 | N/A |
| 3/31/2015 | 45 | -47 | N/A | -59 | N/A |
| 12/31/2014 | 42 | -42 | N/A | -71 | N/A |
| 9/30/2014 | 42 | -38 | N/A | -71 | N/A |
| 6/30/2014 | 41 | -35 | N/A | -71 | N/A |
| 3/31/2014 | 41 | -34 | N/A | -65 | N/A |
| 12/31/2013 | 41 | -33 | N/A | -59 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0QNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).
Earnings vs Market: 0QNA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 0QNA is expected to become profitable in the next 3 years.
Revenue vs Market: 0QNA's revenue (6% per year) is forecast to grow faster than the UK market (3.5% per year).
High Growth Revenue: 0QNA's revenue (6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0QNA's Return on Equity is forecast to be very high in 3 years time (83.8%).